- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01448772
Comparative Bioavailability of Dronabinol Oral Solution Versus Branded Capsule 5 mg Under Fasting Conditions
March 23, 2012 updated by: INSYS Therapeutics Inc
A Single-Dose, Replicate Crossover Design Comparative Bioavailability Study of Dronabinol Oral Solution 5 mg Versus Marinol Capsules 5 mg Under Fasted Conditions
This is a comparative study to assess bioavailability of a proposed alternate dosage form against the current FDA-approved branded product.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
88
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Austin, Texas, United States, 78754
- Worldwide Clinical Trials Drug Development Solutions
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male and female healthy subjects between 18 and 55 years of age, inclusive.
- Subjects must have a body mass index (BMI) within 19 and 29.9 kg/m2, inclusive and weigh a minimum of 50 kg (110 pounds).
- Subjects must be in general good health as determined by medical history, physical examination, or laboratory evaluations conducted at the screening visit and upon admission to the clinic. Examination should include a thorough examination of oral cavity for any abnormal findings.
- Subjects must be non-smokers, defined as not having used any tobacco products in the past six months. Negative results from a urine cotinine test conducted at Screening.
- Subjects must be able to provide informed consent after risks and benefits have been explained, and be willing to comply with study procedures.
- Female subjects of childbearing potential must not be pregnant or nursing; and must be surgically sterile; one year postmenopausal; or on hormonal contraceptive agent(s), diaphragm or condom with spermicidal foam or jelly, or IUD for at least three months prior to drug administration and agree to use the same method of contraception for at least one month after the last drug administration.
- Negative urine pregnancy test at screening and prior to drug administration of each period.
- Negative HIV 1, hepatitis C virus (HCV) antibody, hepatitis B surface antigen within 30 days prior to the start of the study.
- Negative results from screening for drugs of abuse at Screening and Day-1 (check-in) prior to drug administration during all study periods.
Exclusion Criteria:
- Known hypersensitivity or allergy to dronabinol, Marinol, marijuana, hashish, or sesame oil.
- Have participated in an investigational trial within 30 days or six half-lives of the test drug's biologic activity, whichever is longer, before the time of first study dose in this study.
- Presence of visible signs of an infection, mucositis, cold sores, lesions, local irritation, periodontal disease of the oral cavity or any abnormal finding in the oral cavity. In addition, evidence of piercings of the tongue, lip, or anywhere in the oral cavity or a history of oral cavity piercings.
- Have donated or received blood or blood products within 30 days prior to the first study dose.
- Have received any prescription drug (excluding hormonal contraceptives) within 14 days of study drug administration, over-the-counter drugs within seven days of study drug administration, and/or vitamins or herbal supplements within three days of study drug administration.
- Significant bradycardia or tachycardia defined as having a resting heart rate <45 bpm or >100 bpm, respectively.
- Clinical evidence of either hypotension (defined as systolic blood pressure <90 mmHg or diastolic blood pressure <50 mmHg), or hypertension (defined as systolic blood pressure >139 mmHg or diastolic blood pressure >89 mmHg).
- Any history of clinically significant organ system (cardiovascular, neurological, hepatic, hematopoietic, renal, pulmonary, endocrine, or gastrointestinal) disorders or ongoing infectious diseases; or any other conditions that might interfere with the absorption, distribution, metabolism or excretion of the study drug, or that would place the subject at increased risk.
- Use of marijuana (directly or indirectly) within 90 days prior to drug administration and during the course of the study.
- History of treatment for alcohol abuse, significant mental illness, physical dependence to any opioid, barbiturates, amphetamines, cocaine, or benzodiazepines in the past 10 years.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Marinol
|
Comparison of different routes of administration of a drug using the approved Abbott 5 mg capsule product under fasting conditions; two treatment periods with a washout period separating the study periods
|
EXPERIMENTAL: oral solution
|
Comparison of different routes of administration of a drug using a proposed oral solution formulation under fasting conditions; two treatment periods with a washout period separating the study periods
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate and extent of absorption
Time Frame: 48 hours
|
The plasma concentration versus time data of dronabinol and its metabolite (11-hydroxy-delta-9-tetrahydrocannabinol) will be analyzed.
The PK parameters Cmax, AUC0-t and AUCinf for delta-9-tetrahydrocannabinol will be calculated and used as the measures for comparative bioavailability assessment of dronabinol oral solution versus the innovator capsule product.
|
48 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Joe Juren, M.D., Worldwide Clinical Trials
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2011
Primary Completion (ACTUAL)
December 1, 2011
Study Completion (ACTUAL)
December 1, 2011
Study Registration Dates
First Submitted
October 5, 2011
First Submitted That Met QC Criteria
October 6, 2011
First Posted (ESTIMATE)
October 7, 2011
Study Record Updates
Last Update Posted (ESTIMATE)
March 26, 2012
Last Update Submitted That Met QC Criteria
March 23, 2012
Last Verified
March 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Psychotropic Drugs
- Hallucinogens
- Cannabinoid Receptor Agonists
- Cannabinoid Receptor Modulators
- Dronabinol
Other Study ID Numbers
- INS-10-012
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bioavailability
-
Initiator PharmaNot yet recruiting
-
Fundació EurecatURIACH, S.L.Completed
-
WockhardtCompletedBioavailabilityUnited States
-
Midwest Center for Metabolic and Cardiovascular...NaturmegaCompleted
-
University of AarhusCompletedBioavailabilityDenmark
-
Cessatech A/SSmerud Medical Research International AS; Dantrials ApsCompleted
-
University of Maryland, BaltimoreFood and Drug Administration (FDA)Completed
-
Rousselot BVBABioTeSys GmbHCompleted
-
University of UtahCompleted
-
KGK Science Inc.ChromaDex, Inc.Completed
Clinical Trials on Dronabinol Capsules, 5 mg
-
Reata, a wholly owned subsidiary of BiogenAbbVieCompletedMItochondrial MyopathiesUnited States, Denmark
-
Reata, a wholly owned subsidiary of BiogenAbbVie; Friedreich's Ataxia Research AllianceActive, not recruitingFriedreich AtaxiaUnited States, Australia, Austria, Italy, United Kingdom
-
Ligand PharmaceuticalsCompletedType 2 Diabetes MellitusUnited States
-
BioCryst PharmaceuticalsTerminated
-
Zydus Lifesciences LimitedRecruitingAmyotrophic Lateral SclerosisIndia
-
S.L.A. Pharma AGCompletedChronic Pain | Opioid Induced ConstipationGermany, United Kingdom
-
Medical University of ViennaRecruitingRetinal Blood FlowAustria
-
HeNan Sincere Biotech Co., LtdCompleted
-
Reata, a wholly owned subsidiary of BiogenCompletedMelanoma | Unresectable (Stage III) Melanoma | Metastatic (Stage IV) MelanomaUnited States
-
Medicines for Malaria VentureWashington University School of Medicine; Sanaria Inc.; Institute of Tropical... and other collaboratorsCompleted